pharma · Relapsed or Refractory Diffuse Large B-Cell Lymphoma (R/R DLBCL)
Daihong Liu
Daihong Liu clinical programs — 1 development programs from ClinicalTrials.gov with phase, modality, indication, and trial identifiers.
CN HQ
NMPA registrant Type
Company details
- Status
- Public
- HQ
- CN
- Programs
- 1
- Drugs
- 8
- Patents
- 0
Daihong Liu projects
1 ClinicalTrials.gov programs sponsored by Daihong Liu.
Daihong Liu has 1 clinical development programs indexed from ClinicalTrials.gov, including phase, modality, indication text, and linked NCT identifiers.
Clinical programs
Frequently asked questions
How many clinical projects does Daihong Liu have?
1 published programs are linked to this sponsor in our ClinicalTrials.gov index.
Is this the complete company pipeline?
This directory lists published programs for the sponsor in our database. Partnered or out-licensed assets may appear under multiple companies.